DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009

WILMINGTON, Mass., Nov. 6  /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m. ET at the Hotel Sofitel in New York City.  Interested investors can access the live audio webcast of the presentation at http://www.dusapharma.com/.  An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. ® is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy technology platform, and complementary dermatology products.  Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp.  DUSA also markets other dermatology products, including ClindaReach®.  DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients.  DUSA is based in Wilmington, Mass. Please visit our web site at http://www.dusapharma.com/. 

DATASOURCE: DUSA Pharmaceuticals, Inc.



CONTACT:  Chad Rubin, [phone], for DUSA Pharmaceuticals



Web Site:  http://www.dusapharma.com/ 

Copyright